ORKA
Oruka TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive clinical readout, a partnering deal, or early commercial traction could re-rate the stock significantly above the close; upside is concentrated in near-term data/partnering events.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.4.
What can break
Clinical failure, a short cash runway forcing dilutive financing, or regulatory delays would likely produce material downside toward the bear target.
Momentum
97
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.08 · Bull $37.91 · Bear $16.25
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $143.62
Why
Momentum97 · Δ7d +0.4
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
97
26% active weight
Current posture
7d trendImproving
Δ7d
+0.4
Δ21d
+0.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 96.9 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$5.59B
Beta
-0.37
Shares Out
60.31M
P/E (TTM) · Derived
-40.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-49.10
Rev YoY
-
EPS YoY
+14.5%
Gross Margin
-
Op Margin
-
Net Debt
-$335.11M
Current Ratio
23.76
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology